The role of the serotonin transporter in citalopram pharmacological MRI
Completed
- Conditions
- serotonine systeemNA10027946
- Registration Number
- NL-OMON42073
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 45
Inclusion Criteria
Three groups of N = 15 each: healthy female volunteers, aged between 18 and 30 without any harddrug exposure including MDMA.
Exclusion Criteria
Serious general medical condition or one that could interfere in the interpretation of results, use of (5-HT) medication or supplements and / or illicit (hard) drug use within the last 2 weeks, excessive consumption of alcohol (>21 units/ week), caffeine (greater than eight cups of coffee per day) or cigarette (greater than 15 cigarettes per day), allergy to iodine tablets, contraindications for MRI (e.g. ferromagnetic osteosynthetic material, pacemaker, artificial cardiac valves, claustrophobia), abnormal ECG, or pregnant (a pregnancy test will be administered every visit).
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>1. Change score in thalamic [123I]FP-CIT binding ratio between SPECT scan 1 and<br /><br>2 (i.e. SERT occupancy), and the interaction effect with citalopram dose.<br /><br><br /><br>2. Change score in thalamic CBF (phMRI study). This is the difference between<br /><br>baseline CBF and post-citalopram CBF scores. The interaction effect of delta<br /><br>CBF scores and citalopram dose will also be assessed.<br /><br><br /><br>Endpoint: association between SERT occupancy and delta CBF. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Not applicable</p><br>